A Personalized Voice Restoration Device for Patients With Laryngectomy
Launched by WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY · Jul 28, 2022
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new way to help people who have lost their ability to speak due to laryngectomy, a surgery that removes the voice box, or those with severe voice disorders known as dysphonia or aphonia. The researchers are testing a personalized voice restoration device that uses advanced technology to recognize silent speech by picking up signals from the muscles in the face and neck. They believe this innovative approach could successfully help restore communication for patients who struggle with speaking.
To participate in the trial, you need to be an adult aged 18 or older. If you're healthy and have no voice issues, you could join as a healthy volunteer. Alternatively, if you have significant trouble speaking, you may qualify to be part of the group with voice disorders. However, people with completely paralyzed facial muscles cannot participate. This trial is not yet recruiting participants, but it aims to provide new hope for those affected by voice loss.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Group A: Healthy Volunteers
- • 1. Adult subjects, 18 or older
- • 2. Without any voice impairments
- • Group B: Subjects with Aphonia or Dysphonia
- • 1. Adult subjects, 18 or older
- • 2. Documentation of severe dysphonia and/or aphonia, or a GRBAS score \> 0 (GRBAS is a scale that can be used to assess voice quality of subjects who do not have a recorded history of dysphonia or aphonia. The GRBAS scale evaluates for grade, roughness, breathiness, asthenia, and strain).
- Exclusion Criteria:
- • - Group A: Healthy Volunteers
- • 1. Voice impairment
- • Group B: Subjects with Aphonia or Dysphonia
- • 1. Subjects whose face muscles are entirely paralyzed
About Weill Medical College Of Cornell University
Weill Medical College of Cornell University is a leading academic institution dedicated to advancing medical research and education. As a prominent sponsor of clinical trials, it focuses on innovative healthcare solutions and the development of new therapies across various medical disciplines. The institution is committed to fostering collaborative research efforts that enhance patient care and improve health outcomes. With a robust infrastructure and a team of experienced researchers and clinicians, Weill Cornell aims to translate scientific discoveries into practical applications, ensuring a strong emphasis on ethical standards and regulatory compliance throughout the clinical trial process.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Anais Rameau, M.D
Principal Investigator
Weill Medical College of Cornell University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials